CTC-445.2d
A SARS-CoV-2 spike protein RBD binder.
General information
CTC-445.2d is a dimeric polypeptide modified from a monomeric version, which was derived from the human ACE2 receptor, with higher affinity for the SARS-CoV-2 spike protein RBD, intended to be used as a decoy for the virus. The decoy was designed to be inert to the host, selected using yeast display technique for its affinity to RBD and selected to be more stable using directed evolution (Linsky et al., 2020).
Supporting references
| Link | Tested on | Impact factor | Notes | Publication date |
|---|---|---|---|---|
|
Denovo design of potent and resilient hACE2 decoys to neutralize SARS-CoV-2
Spike protein ACE2 Protein factor Animal model In vitro |
hACE2 HEK 293T cells; Calu-3 cells; Balb/c mice; Syrian hamster model for SARS-CoV-2 infection | 41.85 | The dimeric SARS-CoV-2 spike protein RBD decoy shows a 10-fold increase in affinity to its target compared to the monomeric form. It is a strong competitor of the human ACE2 for RBD-binding. The decoy protected cells overexpressing human ACE2 from pseudovirus infection and neutralized the live virus in the lung epithelial cell line (EC50 <5nM) in vitro. Upon intranasal administration, it was present in murine respiratory tract in sufficient concentration and was well tolerated. The decoy protected hamsters in an otherwise lethal viral challenge. |
Nov/05/2020 |
AI-suggested references
| Link | Publication date |
|---|---|
|
De novo design of potent and resilient hACE2 decoys to neutralize SARS-CoV-2
|
Nov/05/2020 |
